Interactions between β-arrestin proteins and the cytoskeletal system, and their relevance to neurodegenerative disorders

Front Endocrinol (Lausanne). 2023 Feb 9:14:957981. doi: 10.3389/fendo.2023.957981. eCollection 2023.

Abstract

β-arrestins, which have multiple cellular functions, were initially described as proteins that desensitize rhodopsin and other G protein-coupled receptors. The cytoskeletal system plays a role in various cellular processes, including intracellular transport, cell division, organization of organelles, and cell cycle. The interactome of β-arrestins includes the major proteins of the three main cytoskeletal systems: tubulins for microtubules, actins for the actin filaments, and vimentin for intermediate filaments. β-arrestins bind to microtubules and regulate their activity by recruiting signaling proteins and interacting with assembly proteins that regulate the actin cytoskeleton and the intermediate filaments. Altered regulation of the cytoskeletal system plays an essential role in the development of Alzheimer's, Parkinson's and other neurodegenerative diseases. Thus, β-arrestins, which interact with the cytoskeleton, were implicated in the pathogenesis progression of these diseases and are potential targets for the treatment of neurodegenerative disorders in the future.

Keywords: Alzheimer’s disease; actin; arrestin; cytoskeleton; microtubule; neurodegeneration.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / metabolism
  • Cytoskeleton* / metabolism
  • Humans
  • Microtubules / metabolism
  • Neurodegenerative Diseases* / metabolism
  • beta-Arrestin 1 / metabolism
  • beta-Arrestins / metabolism

Substances

  • beta-Arrestins
  • Actins
  • beta-Arrestin 1

Grants and funding

This work was supported by the Hungarian National Research, Development and Innovation Office Grants OTKA [K-139231, FK-138862 and PD-124061], the János Bolyai Research Scholarship and János Bolyai Research Scholarship Plus of the Hungarian Academy of Sciences BO/00807/21 and ÚNKP-21-5-SE-29.